A Study of the Effects of Aliskiren in Patients with Idiopathic Membranous Nephropathy

Overview

About this study

The purpose of this study is to assess the effect of aliskiren to keep protein from spilling into the urine in patients who have idiopathic membranous nephropathy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Idiopathic Membranous Nephropathy proven by diagnostic kidney biopsy
  • Age ≥18 years but ≤ 80
  • Proteinuria as measured by urinary protein/urinary creatinine > 4.0 on a spot sample aliquot from a 24-hour urine collection
  • Estimated GFR ≥ 30 ml/min/1.73m^2 using the 4 variable Modification of Diet in Renal Disease (MDRD) equation

Exclusion Criteria

  • Age <18 years
  • Estimated Glomerular Filtration Rate (GFR) < 30 ml/min/1.73m^2, or serum creatinine >3.0 mg/dl
  • Must be off prednisone, calcineurin inhibitor or mycophenolate mofetil for > 1 month and alkylating agents for > 6 months
  • Presence of active infection or a secondary cause of MN (e.g. hepatitis B, HIV, systemic lupus erythematosus (SLE), medications, malignancies).
  • Type 1 or 2 diabetes mellitus
    • Recent history of steroid induced diabetes but no evidence of diabetic nephropathy on renal biopsy performed within 6 months of entry into the study are eligible for enrollment
  • Pregnancy or nursing, for safety reasons
  • Acute renal vein thrombosis documented prior to entry by renal US or CT scan
  • Previous therapy with Aliskiren

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Fernando Fervenza, M.D., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20313713

Mayo Clinic Footer